| Stat3 promotes metastatic progression of prostate cancer J Abdulghani, L Gu, A Dagvadorj, J Lutz, B Leiby, G Bonuccelli, ... The American journal of pathology 172 (6), 1717, 2008 | 313 | 2008 |
| TRAIL receptor signaling and therapeutics J Abdulghani, WS El-Deiry Expert Opinion on Therapeutic Targets 14 (10), 1091-1108, 2010 | 208 | 2010 |
| Autocrine prolactin promotes prostate cancer cell growth via Janus kinase-2-signal transducer and activator of transcription-5a/b signaling pathway A Dagvadorj, S Collins, JB Jomain, J Abdulghani, J Karras, T Zellweger, ... Endocrinology 148 (7), 3089, 2007 | 165 | 2007 |
| Transcription factor Stat5 synergizes with androgen receptor in prostate cancer cells SH Tan, A Dagvadorj, F Shen, L Gu, Z Liao, J Abdulghani, Y Zhang, ... Cancer research 68 (1), 236, 2008 | 126 | 2008 |
| Sorafenib sensitizes solid tumors to Apo2L/TRAIL and Apo2L/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axis J Abdulghani, JE Allen, DT Dicker, YY Liu, D Goldenberg, CD Smith, ... PloS one 8 (9), e75414, 2013 | 58 | 2013 |
| Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents. W Wang, JN Gallant, SI Katz, NG Dolloff, CD Smith, J Abdulghani, ... Cancer biology & therapy 12 (3), 2011 | 56 | 2011 |
| Nuclear Stat5a/b predicts early recurrence and prostate cancer-specific death in patients treated by radical prostatectomy T Mirtti, BE Leiby, J Abdulghani, E Aaltonen, M Pavela, A Mamtani, ... Human Pathology, 2012 | 50 | 2012 |
| Pharmacologic Suppression of JAK1/2 by JAK1/2 Inhibitor AZD1480 Potently Inhibits IL-6–Induced Experimental Prostate Cancer Metastases Formation L Gu, P Talati, P Vogiatzi, AL Romero-Weaver, J Abdulghani, Z Liao, ... Molecular cancer therapeutics 13 (5), 1246-1258, 2014 | 44 | 2014 |
| Sorafenib and quinacrine target anti-apoptotic protein MCL1: a poor prognostic marker in anaplastic thyroid cancer (ATC) J Abdulghani, P Gokare, JN Gallant, D Dicker, T Whitcomb, T Cooper, ... Clinical Cancer Research 22 (24), 6192-6203, 2016 | 41 | 2016 |
| Molecular and genetic markers of follicular-cell thyroid cancer: etiology and diagnostic and therapeutic opportunities. N Goyal, D Setabutr, J Abdulghani, D Goldenberg Advances in experimental medicine and biology 779, 309, 2013 | 15 | 2013 |
| A type II ribonuclease H from Leishmania mitochondria: An enzyme essential for the growth of the parasite S Misra, J Bennett, YN Friew, J Abdulghani, CV Irvin-Wilson, MK Tripathi, ... Molecular and biochemical parasitology 143 (2), 135-145, 2005 | 14 | 2005 |
| Impact of Genetic Targets on Prostate Cancer Therapy H Sheikh, J Abdulghani, S Ali, R Sinha, A Lipton Impact of Genetic Targets on Cancer Therapy, 359-383, 2013 | 6 | 2013 |
| Abstract C41: Nuclear Stat5a/b predicts early recurrence and prostate cancer-specific death in patients treated by radical prostatectomy. T Mirtti, BE Leiby, P Stattin, A Bergh, MT Nevalainen, J Abdulghani, ... Cancer Research 72 (4_Supplement), C41-C41, 2012 | 1 | 2012 |
| Abstract C41: Nuclear Stat5a/b predicts early recurrence and prostate cancer-specific death in patients treated by radical prostatectomy. T Mirtti, BE Leiby, P Stattin, A Bergh, MT Nevalainen, J Abdulghani, ... Cancer Research 72 (4_Supplement), C41-C41, 2012 | 1 | 2012 |
| Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL via up-regulating DR5 and eradicating MCL-1 W Wang, SI Katz, J Abdulghani, D Dicker, WS El-Deiry Cancer Research 70 (8_Supplement), 680-680, 2010 | 1 | 2010 |
| Sorafenib sensitizes hepatocellular carcinoma cells to TRAIL or TRAIL receptor agonist antibodies J Abdulghani, P Mayes, D Dicker, C Smith, R Humphreys, W El Deiry Cancer Research 68 (9_Supplement), 833-833, 2008 | 1 | 2008 |
| Transcription factor Stat3 promotes metastatic progression of prostate cancer L Gu, J Abdulghani, A Dagvadorj, J Lutz, G Bonuccelli, MP Lisanti, ... The Journal of Urology 179 (4), 392, 2008 | 1 | 2008 |
| Targeting of NOXA overexpression in anaplastic thyroid cancer (ATC) NK Finnberg, J Abdulghani, H Ehya, W El-Deiry Cancer Research 77 (13_Supplement), 5636-5636, 2017 | | 2017 |
| The drug combination sorafenib and quinacrine targets the expression of Mcl-1-an anti-apoptotic protein and candidate prognostic factor in Anaplastic Thyroid Cancer (ATC) J Abdulghani, JN Gallant, P Gokare, T Cooper, T Whitcomb, J Liao, J Liu, ... Cancer Research 75 (15_Supplement), 2527-2527, 2015 | | 2015 |
| Quinacrine and sorafenib as potential combination for anaplastic thyroid carcinoma. J Abdulghani, JN Gallant, T Whitcomb, D Dicker, D Goldenberg, CD Smith, ... Cancer Research 73 (8_Supplement), 608-608, 2013 | | 2013 |
